Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer Review

Industry Collaboration International Collaboration

cited authors

  • Yang, James Chih-Hsin; Zhou, Caicun; Janne, Pasi A.; Ramalingam, Suresh S.; Kim, Tae Min; Riely, Gregory J.; Spira, Alexander, I; Piotrowska, Zofia; Mekhail, Tarek; Campelo, Maria Rosario Garcia; Felip, Enriqueta; Bazhenova, Lyudmila; Jin, Shu; Kaur, Manmit; Diderichsen, Paul M.; Gupta, Neeraj; Bunn, Veronica; Lin, Jianchang; Churchill, Eric; Mehta, Minal; Nguyen, Danny

authors

Publication Date

  • December 29, 2022

webpage

published in

category

keywords

  • Carcinoma
  • adverse reactions
  • drug-related side effects
  • epidermal growth factor receptor
  • non-small cell lung
  • patient safety
  • protein tyrosine kinases

start page

  • 95

end page

  • 106

volume

  • 23

issue

  • 1